Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 3.42
NAS:ARRY's Cash-to-Debt is ranked lower than
73% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. NAS:ARRY: 3.42 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:ARRY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.49  Med: 1.66 Max: No Debt
Current: 3.42
Equity-to-Asset 0.45
NAS:ARRY's Equity-to-Asset is ranked lower than
92% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:ARRY: 0.45 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:ARRY' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.55  Med: 0.22 Max: 0.93
Current: 0.45
-1.55
0.93
Debt-to-Equity 0.60
NAS:ARRY's Debt-to-Equity is ranked lower than
99% of the 487 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. NAS:ARRY: 0.60 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:ARRY' s Debt-to-Equity Range Over the Past 10 Years
Min: -18.96  Med: -0.7 Max: 18.79
Current: 0.6
-18.96
18.79
Debt-to-EBITDA -1.22
NAS:ARRY's Debt-to-EBITDA is ranked lower than
99.99% of the 209 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. NAS:ARRY: -1.22 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NAS:ARRY' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -13.41  Med: -1.42 Max: 4.6
Current: -1.22
-13.41
4.6
Piotroski F-Score: 3
Altman Z-Score: 2.77
Beneish M-Score: -3.59
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -80.37
NAS:ARRY's Operating Margin % is ranked higher than
55% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. NAS:ARRY: -80.37 )
Ranked among companies with meaningful Operating Margin % only.
NAS:ARRY' s Operating Margin % Range Over the Past 10 Years
Min: -410.11  Med: -63.65 Max: 6.34
Current: -80.37
-410.11
6.34
Net Margin % -89.30
NAS:ARRY's Net Margin % is ranked higher than
53% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. NAS:ARRY: -89.30 )
Ranked among companies with meaningful Net Margin % only.
NAS:ARRY' s Net Margin % Range Over the Past 10 Years
Min: -511.63  Med: -83.68 Max: 18.05
Current: -89.3
-511.63
18.05
ROE % -237.23
NAS:ARRY's ROE % is ranked lower than
100% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. NAS:ARRY: -237.23 )
Ranked among companies with meaningful ROE % only.
NAS:ARRY' s ROE % Range Over the Past 10 Years
Min: -3933.07  Med: -132.15 Max: 110.67
Current: -237.23
-3933.07
110.67
ROA % -42.73
NAS:ARRY's ROA % is ranked lower than
64% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. NAS:ARRY: -42.73 )
Ranked among companies with meaningful ROA % only.
NAS:ARRY' s ROA % Range Over the Past 10 Years
Min: -99.03  Med: -51.46 Max: 5.6
Current: -42.73
-99.03
5.6
ROC (Joel Greenblatt) % -1460.93
NAS:ARRY's ROC (Joel Greenblatt) % is ranked lower than
65% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. NAS:ARRY: -1460.93 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:ARRY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1460.93  Med: -321.97 Max: 297.05
Current: -1460.93
-1460.93
297.05
3-Year Revenue Growth Rate 39.40
NAS:ARRY's 3-Year Revenue Growth Rate is ranked higher than
84% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NAS:ARRY: 39.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:ARRY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -35.9  Med: -2.2 Max: 39.8
Current: 39.4
-35.9
39.8
3-Year EBITDA Growth Rate 2.90
NAS:ARRY's 3-Year EBITDA Growth Rate is ranked higher than
51% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. NAS:ARRY: 2.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:ARRY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -66.3  Med: 2.7 Max: 105.1
Current: 2.9
-66.3
105.1
3-Year EPS without NRI Growth Rate 1.40
NAS:ARRY's 3-Year EPS without NRI Growth Rate is ranked higher than
52% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. NAS:ARRY: 1.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:ARRY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -50.5  Med: 1.4 Max: 55.7
Current: 1.4
-50.5
55.7
GuruFocus has detected 4 Warning Signs with Array BioPharma Inc NAS:ARRY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:ARRY's 30-Y Financials

Financials (Next Earnings Date: 2018-02-09)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

ARRY Guru Trades in Q4 2016

Steven Cohen 1,570,641 sh (New)
Jim Simons Sold Out
Paul Tudor Jones Sold Out
Joel Greenblatt Sold Out
Ken Fisher 65,693 sh (-51.66%)
» More
Q1 2017

ARRY Guru Trades in Q1 2017

Caxton Associates 15,900 sh (New)
Ken Fisher 78,014 sh (+18.76%)
Steven Cohen 500,000 sh (unchged)
Steven Cohen 1,277,900 sh (-18.64%)
» More
Q2 2017

ARRY Guru Trades in Q2 2017

Jim Simons 990,441 sh (New)
Paul Tudor Jones 73,373 sh (New)
Steven Cohen 2,406,000 sh (+88.28%)
Ken Fisher 134,180 sh (+71.99%)
Caxton Associates Sold Out
» More
Q3 2017

ARRY Guru Trades in Q3 2017

Louis Moore Bacon 100,000 sh (New)
Steven Cohen 9,008,999 sh (+274.44%)
Paul Tudor Jones 75,184 sh (+2.47%)
Ken Fisher 134,180 sh (unchged)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NAS:ARRY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2017-06-30 Add 71.99%$6.96 - $9.07 $ 11.2137%134,180
Ken Fisher 2017-03-31 Add 18.76%$8.56 - $12.56 $ 11.215%78,014
Ken Fisher 2016-12-31 Reduce -51.66%$5.38 - $8.8 $ 11.2152%65,693
Joel Greenblatt 2016-12-31 Sold Out $5.38 - $8.8 $ 11.2152%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:SPPI, LSE:GNS, ROCO:4147, OSTO:VITR, NAS:RARE, NAS:IMMU, XKRX:086900, OCSE:ALK B, NYSE:XON, NAS:XLRN, XKRX:084990, SZSE:300009, NYSE:EBS, XMCE:ALM, SHSE:600645, XKRX:006280, NAS:INSM, HKSE:01548, SZSE:002275, NAS:RGEN » details
Traded in other countries:AR2.Germany,
Headquarter Location:USA
Array BioPharma Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer.

Array BioPharma Inc was incorporated in Delaware on February 6, 1998. It is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Its clinical stage drugs include Binimetinib, Encorafenib, Selumetinib, Tucatinib/ONT-380, ARRY-382, LOXO-292 and LOXO-195 among others. The company has geographical presence in North America, Europe and Asia Pacific.

Top Ranked Articles about Array BioPharma Inc

Array BioPharma Announces Private Exchange of $107 Million of its 3.00% Convertible Senior Notes due 2020 for its 2.625% Convertible Senior Notes due 2024 and Shares of its Common Stock
Array BioPharma Reports Initial Results From Novel Immunotherapy Combination At The Society For Immunotherapy Of Cancer (SITC) 32nd Annual Meeting
Array BioPharma To Present At The 2017 Stifel Healthcare Conference
Factors of Influence in 2018, Key Indicators and Opportunity within AGNC Investment, Discovery Communications, Array BioPharma, Callon Petroleum, People's United, and DDR – New Research Emphasizes Economic Growth
Steven Cohen Takes Stake in Karyopharm Therapeutics Guru increases position in health care space
Point72 Asset Management founder Steven Cohen (Trades, Portfolio) established a holding in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) on Nov. 3, further expanding his large positioning in the health care space. Read more...
Array BioPharma Reports Financial Results For The First Quarter Of Fiscal 2018
Array Biopharma To Report Financial Results For The First Quarter Of Fiscal 2018 On October 31, 2017
Steven Cohen Doubles Down on Sickle Cell Disease Therapeutics Company Global Blood Guru adds approximately 225% to the position
On Oct. 2, Steven Cohen (Trades, Portfolio) increased his Global Blood Therapeutics Inc. (NASDAQ:GBT) position, according to GuruFocus real-time picks. Read more...
Array BioPharma To Present At The 2017 Cantor Fitzgerald Global Healthcare Conference
Array BioPharma Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

Ratios

vs
industry
vs
history
PB Ratio 9.68
ARRY's PB Ratio is ranked lower than
99% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. ARRY: 9.68 )
Ranked among companies with meaningful PB Ratio only.
ARRY' s PB Ratio Range Over the Past 10 Years
Min: 3.52  Med: 16.25 Max: 135.59
Current: 9.68
3.52
135.59
PS Ratio 13.53
ARRY's PS Ratio is ranked lower than
53% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. ARRY: 13.53 )
Ranked among companies with meaningful PS Ratio only.
ARRY' s PS Ratio Range Over the Past 10 Years
Min: 1.44  Med: 7.65 Max: 24.4
Current: 13.53
1.44
24.4
EV-to-EBIT -16.55
ARRY's EV-to-EBIT is ranked lower than
99.99% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. ARRY: -16.55 )
Ranked among companies with meaningful EV-to-EBIT only.
ARRY' s EV-to-EBIT Range Over the Past 10 Years
Min: -44  Med: -6 Max: 320.9
Current: -16.55
-44
320.9
EV-to-EBITDA -16.85
ARRY's EV-to-EBITDA is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. ARRY: -16.85 )
Ranked among companies with meaningful EV-to-EBITDA only.
ARRY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -76.5  Med: -6.5 Max: 165.9
Current: -16.85
-76.5
165.9
EV-to-Revenue 13.32
ARRY's EV-to-Revenue is ranked lower than
51% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. ARRY: 13.32 )
Ranked among companies with meaningful EV-to-Revenue only.
ARRY' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.1  Med: 7.7 Max: 27.9
Current: 13.32
2.1
27.9
Current Ratio 5.43
ARRY's Current Ratio is ranked lower than
53% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. ARRY: 5.43 )
Ranked among companies with meaningful Current Ratio only.
ARRY' s Current Ratio Range Over the Past 10 Years
Min: 0.81  Med: 2.98 Max: 7.86
Current: 5.43
0.81
7.86
Quick Ratio 5.43
ARRY's Quick Ratio is ranked higher than
50% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. ARRY: 5.43 )
Ranked among companies with meaningful Quick Ratio only.
ARRY' s Quick Ratio Range Over the Past 10 Years
Min: 0.81  Med: 2.95 Max: 7.55
Current: 5.43
0.81
7.55
Days Sales Outstanding 68.70
ARRY's Days Sales Outstanding is ranked lower than
57% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. ARRY: 68.70 )
Ranked among companies with meaningful Days Sales Outstanding only.
ARRY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.61  Med: 50.33 Max: 497.21
Current: 68.7
4.61
497.21
Days Payable 84.62
ARRY's Days Payable is ranked higher than
68% of the 434 Companies
in the Global Biotechnology industry.

( Industry Median: 57.10 vs. ARRY: 84.62 )
Ranked among companies with meaningful Days Payable only.
ARRY' s Days Payable Range Over the Past 10 Years
Min: 37.58  Med: 76.12 Max: 159.87
Current: 84.62
37.58
159.87

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -9.10
ARRY's 3-Year Average Share Buyback Ratio is ranked higher than
62% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. ARRY: -9.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ARRY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -111.3  Med: -11.65 Max: -4.2
Current: -9.1
-111.3
-4.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 11.68
ARRY's Price-to-Net-Cash is ranked lower than
99.99% of the 543 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. ARRY: 11.68 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ARRY' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.76  Med: 7.3 Max: 141.11
Current: 11.68
2.76
141.11
Price-to-Net-Current-Asset-Value 10.10
ARRY's Price-to-Net-Current-Asset-Value is ranked lower than
100% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 7.12 vs. ARRY: 10.10 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ARRY' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.24  Med: 6.98 Max: 418.5
Current: 10.1
2.24
418.5
Price-to-Tangible-Book 9.66
ARRY's Price-to-Tangible-Book is ranked lower than
99% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. ARRY: 9.66 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ARRY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.14  Med: 4.48 Max: 123.09
Current: 9.66
1.14
123.09
Price-to-Median-PS-Value 1.77
ARRY's Price-to-Median-PS-Value is ranked lower than
79% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. ARRY: 1.77 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ARRY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.19  Med: 0.89 Max: 2.89
Current: 1.77
0.19
2.89
Earnings Yield (Greenblatt) % -6.05
ARRY's Earnings Yield (Greenblatt) % is ranked higher than
57% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. ARRY: -6.05 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ARRY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -95.2  Med: -14 Max: 5.1
Current: -6.05
-95.2
5.1

More Statistics

Revenue (TTM) (Mil) $141.33
EPS (TTM) $ -0.75
Beta1.56
Short Percentage of Float14.98%
52-Week Range $6.73 - 13.40
Shares Outstanding (Mil)197.03

Analyst Estimate

Jun18
Revenue (Mil $)
EPS ($) -1.19
EPS without NRI ($) -1.19
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}